Global Approach in Safety Testing ICH Guidelines Explained /

The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a unique project that brings together the regulatory authorities of Europe, Japan and the US and experts from the pharmaceutical industry in the three regions to discuss...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: van der Laan, Jan Willem (Επιμελητής έκδοσης), DeGeorge, Joseph J. (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: New York, NY : Springer New York : Imprint: Springer, 2013.
Σειρά:AAPS Advances in the Pharmaceutical Sciences Series, 5
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
Πίνακας περιεχομένων:
  • The  International Conference on Harmonisation. History of Safety Guidelines
  • EU Perspective on ICH
  • The Value and Benefits of the International Conference on Harmonisation (ICH) to Drug Regulatory Authorities Advancing Harmonization for Better Public Health
  • A Japanese Perspective on Implementation of the Three Rs: Incorporating Best Scientific Practices into Regulatory Process
  • Towards more Scientific Relevance in Carcinogenicity Testing
  • The Evolution, Scientific Reasoning and Use of ICH S2 Guidelines for Genotoxicity Testing of Pharmaceuticals
  • Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies , Where are we now; an  S3A/S3B update (1995-2011)
  • Duration of Acute and Chronic Toxicity Testing in Animals (ICH S4A and S4B)
  • Why and how did Reproduction Toxicity Testing make its early entry into and Rapid Success in ICH?
  • ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
  • Safety Pharmacology: Guidelines S7A and S7B
  • ICH S8:  History and Perspectives
  • ICH S9: Nonclinical Evaluation of Anticancer Pharmaceuticals a Perspective from Regulators on the Development of the Guideline
  • Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals ICH M3 and M3(R2).